Drug Profile
Epoetin alfa biosimilar - LG Chem
Alternative Names: EPO; EspogenLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer CHA University; Chong Kun Dang; LG Chem; LG Life Sciences; Ministry of Health & Welfare, Korea
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Cell stimulants; Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
- Phase II Cerebral palsy
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Anaemia in China (Parenteral)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Anaemia in China (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cerebral-palsy(Combination therapy, In children, In infants) in South Korea